Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EpiPen Alternative Could Hit Pharmacy Shelves Next Year

XTALKS VITALS NEWS

EpiPen

A two-pack of EpiPens now sells for $608, which is a 548 percent price increase over the product’s cost ten years ago.

Share this!

October 27, 2016 | by Sarah Hand, M.Sc.

While Mylan’s controversial EpiPen currently holds significant market share, the medical device is about to face some stiff competition. Kaleo Pharma – the company that owns the rights to a rival medical device – will reportedly begin marketing their product in early 2017.

The device, called Auvi-Q, was previously sold by Sanofi, however it was pulled from the market in 2015 amid concerns that the auto-injector was delivering inaccurate doses of epinephrine. Kaleo has yet to announce details regarding the pricing of the medical device.

“We’re focusing on returning Auvi-Q to the market as an alternative product that all patients can afford,” Kaleo chief executive Spencer Williamson told StatNews. “… We understand that price is central to this conversation. … I can assure you that at the end of the day, after we work with all the stakeholders, patients will have a low out-of-pocket cost.”

Kaleo’s decision to reintroduce the medical device comes at an opportune time as pricing for the EpiPen has become a controversial topic. Mylan is just one of the companies in the pharmaceutical and medical device industries who has faced criticism for their pricing practices.



A two-pack of EpiPens now sells for $608, which is a 548 percent price increase over the product’s cost ten years ago. In response to the rising costs, which are being passed from insurers onto patients, Mylan could begin selling a generic version of the EpiPen for $300.

Currently, the only available alternative to the EpiPen is a medical device known as the Adrenaclick, marketed by Amedra Pharmaceuticals. The device has seen an increased number of prescriptions lately, as physicians seek to help patients find a lower-cost version of the lifesaving medication.

While Teva Pharmaceuticals and Adamis have been developing EpiPen alternatives of their own, the US Food and Drug Administration (FDA) has not yet approved these devices. The regulatory agency has faced criticism over their approval processes, particularly when it comes to products, like the EpiPen, who have a near-monopoly on the market.

Like Mylan, Kaleo has recently been involved in some drug pricing inquiries of their own. In early 2016, Kaleo was contacted by two US Senators regarding the company’s decision to raise the price of an old drug, used to reverse opioid overdoses.

According to Kaleo, in an effort to get the Auvi-Q back on the market, they have “conducted a thorough manufacturing assessment and invested in new technology and quality systems to ensure accurate, reliable and consistent delivery from the product.” At present, it’s unclear exactly what regulatory steps Kaleo has taken to get this EpiPen alternative back into the pharmacy.


Keywords: Medical Device, Pharmaceutical Pricing, Prescriptions


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.